|
Published by: SMI Publishing, Ltd
Published: Mar. 20, 2002
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Ratko Djukanovic, Senior Lecturer in Medicine, University of Southampton.
- 9.10 GENERAL OVERVIEW
- Epidemiological, economic and commercial issues
- Disease overview and burden
- Causes of asthma
- Existing therapies: drug groups, efficacy and safety
- Future trends in disease and treatment
- Dr Joan Soriano, Director, Worldwide Epidemiology, Glaxosmithkline.
- 9.40 UNMET NEEDS
- Focusing resources on relevant therapeutic areas
- New methods for reduction of side effects caused by asthma therapeutics
- Improving patient compliance
- Generic versus branded medications
- Recombinant monoclonal antibodies
- Genes and asthma
- Predictions for future direction of asthma research
- Dr Theodore Reiss, Executive Director, Respiratory & Allergy, Merck Research Laboratories.
- 10.20 CLINICAL STUDIES
- New drugs for asthma
- Medical burden and needs, GCP and CPMP guidelines
- Inhaled beta-agonists, inhaled steroids and leukotriene antagonists
- Phase II proof of concept studies
- Anti-IgE, anti-IL-5, CCR3 antagonism, IL-4 and TNFĄ directed therapy
- Immunotherapy and disease modification
- Dr Trevor Hansel, Medical Director, Royal Brompton Clinical Studies Unit.
- 11.00 Morning Coffee
- 11.20 NOVEL TREATMENTS FOR ASTHMA
- Asthma therapy: what’s in the pipeline
- New Products
- Kinase inhibitors (JNK, p38, IKK)
- Cytokine modulators
- Options for oral immunotherapy
- Dr Alan Lewis, President, Celgene.
- 12.00 A NEW DIMENSION IN LUNG IMAGING
- A new dimension in lung imaging
- Introducing radionuclide imaging studies
- Improving 2D data analysis
- Using 3D SPECT imaging
- Development of a novel radiolabelling technique
- Dr Peter H. Hirst, Head of Inhalation Business Development, Pharmaceutical Profiles.
- 12.40 Networking Lunch
- 1.40 THE ROLE OF IL-4R IN ASTHMA
- A new generation of immune system therapeutic proteins
- The immune response in asthma patients
- Interactions between immune system proteins in asthma
- IL-4R-mediated responses in asthma
- Therapeutic efficiency of blocking IL-4 vs IL-4R
- Dr Joel Tocker, Staff Scientist, AMGEN.
- 2.20 TREATMENT FOR PERSISTENT ASTHMA
- Anti-IL-4 and anti-IL-2 receptor antibodies
- Asthma is a T-cell mediated disease
- TH2 cells are important components of the asthma pathophysiology
- IL-4 is an important mediator of TH2 cell development and IgE production
- Blocking IL-4 may suppress some of the more severe and chronic symptoms of asthma
- Activated T cells are prominent in the lungs of asthmatics
- Blocking IL-2- mediated stimulation of T cells may reduce T cell activation in this disease
- Dr Roy Levitt, Executive Vice President, Chief Operating Officer, Magainin.
- 3.00 ANTIINFLAMMATORY THERAPIES
- Chemokine receptor antagonists
- Chemokine receptors and their ligands
- Chemokines as mediators of inflammation
- Eotaxin, eosinophils and the CCR3 receptor
- Development of small molecule CCR3 antagonists
- Effect of CCR3 antagonists in animal models of asthma
- Future directions
- Dr Paul Gater, Principal Scientist, F. Hoffmann-La Roche.
- 3.40 Afternoon Tea
- 4.00 THERAPEUTICS FOR CHRONIC LUNG DISEASES
- Phosphodiesterase 4 inhibitors
- The role of PDE4 in modulating the activity of inflammatory and immunocompetent cells
- Dual benefits of PDE4 selective inhibitors
- Advantages of PDE4 inhibitors over existing therapies
- Clinical efficacy of oral PDE4 inhibitors
- Animal models
- Reducing the side effects of PDE4 inhibitors
- Dr Rikki Alexander, Principal Scientist, UCB-Celltech.
- 4.40 SELICIDS
- Novel treatments for respiratory disease
- Novel PDE4 inhibitors
- Unique chemistry
- PDE4 subtype selectivity
- Cytokine modulation
- Improved therapeutic index
- Clinical progress
- Dr David Stirling, Chief Scientific Officer, Executive Vice President, Celgene Corporation.
- 5.20 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Re-registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Mike Placke, VP Business Development, Battelle.
- 9.10 GENETIC TARGETS FOR ASTHMA THERAPY
- Asthma-directed drug design
- Identifying human genes associated with asthma
- Genes showing potential as targets for asthma therapy
- Target validation using viruses
- Developing drugs from genes associated with asthma
- Case study
- Speeding up drug discovery via strategic alliances
- Dr Neil Bacon, Chief Executive, Doctors.net.uk.
- 9.40 THE SEARCH FOR ANTI-ASTHMA DRUGS
- Past, present & future
- Potential therapeutic targets (chemical, cellular, molecular)
- Approaches for the identification of novel targets
- Target validation: the new challenge
- Applicability of animal models in target identification
- Influence of infections
- Case studies; Future Directions
- Dr Ivan Richards, Senior Fellow, Pfizer.
- 10.20 ALLERGY VACCINATION
- Treating the cause of asthma
- Basic mode of action
- Clinical efficacy; disease modification, curative potential
- Novel approaches to allergy vaccination therapies
- Dr Torbjørn Bjerke, Executive Vice President Research & Development,, ALK-Abello A/S.
- 11.00 Morning Coffee
- 11.20 RESPIRATORY AND NASAL DRUG DELIVERY
- Revolutionising asthma inhalers
- Alternatives to CFC inhalers
- Extra fine droplets for improved delivery to the airways
- Dose counters
- Powder inhaler technologies
- Bronchodilators, an example of delivery
- Metered dose powder inhalers
- Dr Steve Nichols, New Technology Coordination Manager, Sanofi-Aventis.
- 12.00 SUCCESSFUL PULMONARY DRUG DELIVERY
- Overcoming the barriers
- Understanding the problems facing delivery of drugs to the lungs
- An overview of novel inhalation devices and technologies
- Adaptive Aerosol Delivery (AAD™) - improving the interface between the patient the medication and the device
- The patient centred benefits of 'Intelligent Inhalation' technology
- Mr Jonathan Rigby, Business Development Manager, Profile Therapeutics Plc.
- 12.40 Networking Lunch
- 1.40 DRY POWDER INHALER TECHNOLOGY
- Development challenges and commercial opportunities
- Dry powder inhalers in the context of other delivery formats
- The future for dry powder inhalers
- Critical development challenges and regulatory hurdles
- New technologies which provide solutions
- Dr Mark Parry-Billings, Director, Research and Development, Innovata Biomed.
- 2.20 CONTROLLING ASTHMA
- Asthma treatment - a question of effective drugs & effective delivery
- How well is asthma currently controlled
- BTS & NICE Guidance
- The problems of drug delivery
- Improving delivery and Easi-Breathe case study
- Asthma drug delivery in the future
- Dr David Fakes, Technical Affairs Director, IVAX Pharmaceuticals.
- 3.00 INCREASING DRUG APPLICABILITY
- Pulmonary drug delivery using AERx® technology
- Liquid formulation technology
- High drug loading per breath
- Point-of-use aerosol generation and active breath control for efficiency and precision of drug delivery
- Electronic compliance monitoring
- Case studies involving drugs for respiratory disease
- Dr Stephen Farr, Senior VP & CSO, Aradigm Corporation.
- 3.40 Afternoon Tea
- 4.00 RESPIRATORY PRODUCT DEVELOPMENT
- External influences
- MDI propellants and the environment
- Industrial property
- CMC regulatory
- Feedback from systemic and competitors
- Complexity versus cost
- Dr Paul Wright, Associate Director, Product Development, AstraZeneca .
- 4.40 BUILDING AN ONLINE COMMUNITY
- Asthma e-marketing
- How pharmaceutical companies use the web
- A doctor-only community
- Patient information: compliance tools/ educational literature
- Integrating with offline methods and the sales force
- Dr Neil Bacon, Chief Executive, Doctors.net.uk.
- 5.20 Chairman's Closing Remarks and Close of Conference
AbstractMissed an SMi Conference? Of course nothing compares with being there. But if you missed the recent SMi Conference on Asthma Therapeutics Third Annual Event did you know you can still benefit from the event?
What the information package includes:
- pages of presentations
- the latest trends, industry data, forecasts, market analysis, competitor information, and much, much more.
Events are now available on CD-ROM, via .pdf, in hardcopy documentation and on audiocassette. There's no need to miss out on any key industry conferences - whether you could not make the dates, or you got tied up in last minute business meetings, you and your colleagues can still benefit. Take this unique opportunity to benefit from the market leaders' strategies. You can work through the conference materials at your leisure, whenever you want. The packages are now available in hardcopy or electronically. All conference documentation packages are dispatched once payment has been received after the event. Order online today to secure your copy.
Conference documentation features all the PowerPoint presentations and handouts from the event. Whether you're writing a report based on the latest industry trends, training colleagues or undertaking research, the documentation offers an invaluable source of leading edge knowledge.
Or capture all of the information presented at our conferences on professionally recorded audiocassettes. Your purchase includes a permanent reference of audiocassettes and the complete conference workbook.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
